Skip to main content

Table 1 Summary on the role of iron chelators in leukemia

From: Iron and leukemia: new insights for future treatments

Name Properties Type of leukemia Mode of action Ref.
DFO FDA-approved iron chelator AML, ALL Inhibits proliferation, induces apoptosis, differentiation and G1/S cell cycle arrest; inhibits ribonucleotide reductase, decreases the cyclin-dependent kinase inhibitor p21CIP1/WAF1 protein, induces ROS generation, activates IFN-γ/STAT1 and MAPK pathway. [14, 80, 83,84,85]
DFX FDA-approved iron chelator AML, ALL Inhibits proliferation and induces differentiation; induces ROS generation, inhibits NF-κB and mTOR signaling pathway, restores GVL. [14, 16, 79, 86, 87]
3-AP 3-aminopyridine-2-carboxaldehyde thiosemicarbazone AML, ALL Inhibits ribonucleotide reductase. [88]
SIHA Tridentate iron chelator AML Induces apoptosis, cell cycle arrest and dissipation of the mitochondrial membrane potential. [89]
Dp44mT Di-pyridylketone thiosemicarbazone AML, ALL Induces apoptosis and G1/S cell cycle arrest; activates MAPK pathway. [90]
EP Thrombopoietin receptor agonist AML Induces differentiation and G1 cell cycle arrest. [15]
CPX Fungicide AML, ALL, CML Inhibits ribonucleotide reductase. [91, 92]